(Q40759966)

23 September 2017

title

Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. (English)

1 reference

23 September 2017

4

1 reference

23 September 2017

P W Stone

1

1 reference

23 September 2017

S Teutsch

2

1 reference

23 September 2017

R H Chapman

3

1 reference

23 September 2017

S J Goldie

5

1 reference

23 September 2017

P J Neumann

6

1 reference

23 September 2017

publication date

1 July 2000

1 reference

American Journal of Preventive Medicine

23 September 2017

published in

1 reference

23 September 2017

volume

19

1 reference

23 September 2017

issue

1

1 reference

23 September 2017

page(s)

15-23

1 reference

An ounce of prevention ... what are the returns? Second edition, 1999.

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Prevention, policy, and paradox: what is the value of future health?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-per-QALY league tables: their role in pharmacoeconomic analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-effectiveness league tables: More harm than good?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Interpreting cost analyses of clinical interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-utility in practice: a policy maker's guide to the state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Raising the quality of cost-utility analyses: lessons learnt and still to learn

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Evaluating the cost-effectiveness of clinical and public health measures

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

The measurement of indirect costs in the health economics evaluation literature. A review

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Are methods for estimating QALYs in cost-effectiveness analyses improving?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Methods of cost-effectiveness analysis: areas of consensus and debate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost effectiveness of vaccination against pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-effectiveness evaluation of vaccination against Haemophilus influenzae invasive diseases in France

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Setting priorities for the Children's Vaccine Initiative: a cost-effectiveness approach

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-effectiveness of antibiotic prophylaxis for dental procedures in patients with artificial joints

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Chemoprophylaxis of prosthetic joint patients during dental treatment: A decision-utility analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Estrogen use in postmenopausal women--costs, risks, and benefits

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-effectiveness of hormone replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Screening for hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Is screening for abdominal aortic aneurysm worthwhile?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Screening for abdominal aortic aneurysm: a computer assisted cost-utility analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-Effectiveness of Screening for Carotid Stenosis in Asymptomatic Persons

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-effectiveness of the North Karelia Hypertension Program. 1972-1977

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

In search of the best upper age limit for breast cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

A cost utility analysis of mammography screening in Australia.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Screening for prostate cancer. A decision analytic view

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Parasite screening and treatment among Indochinese refugees. Cost-benefit/utility and the General Health Policy Model

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Tuberculin screening: cost-effectiveness analysis of various testing schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Case-finding for unsuspected thyroid disease: costs and health benefits.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-effectiveness of HIV-prevention skills training for men who have sex with men.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

A cost-effectiveness analysis of exercise as a health promotion activity

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

The cost-effectiveness of a cardiovascular risk reduction program in general practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Where Now for Saving Lives?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Efficacy and cost-effectiveness of autologous blood predeposit in patients undergoing radical prostatectomy procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

The cost effectiveness of preoperative autologous blood donations

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Intraoperative autologous transfusion during elective infrarenal aortic reconstruction: a decision analysis model

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Gains in life expectancy from medical interventions--standardizing data on outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Use of economic evaluation guidelines: 2 years' experience in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

Evaluating the BMJ guidelines for economic submissions: prospective audit of economic submissions to BMJ and The Lancet

1 reference

https://api.crossref.org/works/10.1016%2FS0749-3797%2800%2900151-3

7 January 2021

10.1016/S0749-3797(00)00151-3

Identifiers

DOI

1 reference

23 September 2017

1 reference